On August 3, Eli Lilly declined 3.21% in regular trading, trading at approximately $1,122.99 per share, with turnover of $724 million. The stock had risen nearly 2% in pre-market trading before reversing sharply during the session.

On the news front, Eli Lilly announced that its drug Olomorasib received FDA Breakthrough Therapy Designation as a monotherapy for adults with KRAS G12C-mutant advanced pancreatic cancer who have received at least one prior systemic therapy. The designation was based on preliminary results from a Phase 1/2 study. However, this pipeline positive failed to offset broader concerns about slowing GLP-1 prescription growth, following recent warnings from Cigna about decelerating demand trends.

Additionally, with Eli Lilly set to report earnings on August 5, where consensus expects revenue of approximately $20.7 billion (up 40.78% YoY) and adjusted EPS of $6.01, investors appeared to be reducing risk exposure ahead of the release. The broader pharmaceutical sector also traded lower, with AstraZeneca down 7.75%, Johnson and Johnson down 1.65%, Merck down 1.27%, and Bristol-Myers Squibb down 1.02%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)